AstraZeneca's announcement of a £450m investment to expand its vaccine plant in Liverpool was met with optimism from the company and the UK government. This move comes after a period of strained relations between the life sciences sector and the government post-Covid. The investment, designed to boost vaccine-making capacity, counters earlier criticisms from AstraZeneca's CEO regarding the UK's tax competitiveness. Despite needing mutual agreement for the expansion, the collaboration reflects a shift in sentiment towards developing the UK as a global life sciences leader.
AstraZeneca's £450m investment in Liverpool's vaccine plant was a declared vote of confidence in the UK as a life sciences superpower amid a troubled industry-government relationship.
The announcement of AstraZeneca's expansion, coupled with a commitment to invest in research, was aimed at signaling a new phase in UK life sciences post-pandemic.
Collection
[
|
...
]